Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Aerovate Therapeutics, Inc. (Note: The input metadata references "Jade Biosciences," but the filing text explicitly identifies the registrant as Aerovate Therapeutics, Inc.) on June 21, 2022. The record date for the meeting was April 22, 2022, with 24,410,393 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders approved the election of Timothy P. Noyes and Mark Iwicki as Class I directors to serve until the 2025 Annual Meeting.
- Timothy P. Noyes: 9,910,723 votes For; 639,615 votes Withheld; 1,982,488 Broker Non-Votes.
- Mark Iwicki: 8,927,284 votes For; 1,623,054 votes Withheld; 1,982,488 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Results: 12,532,242 votes For; 401 votes Against; 183 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the correct registrant name is Aerovate Therapeutics, Inc. (AVTE), not Jade Biosciences, Inc.
- Confirm the successful election of Timothy P. Noyes and Mark Iwicki to the Board of Directors.
- Note the significant number of broker non-votes (1,982,488) recorded for the director election proposals.
- Confirm KPMG LLP has been ratified as the independent auditor for the 2022 fiscal year.